GlassScriptPhysician profile
Narayana Gowda
NPI 1417341090
$3,409.40
in general payments reported to CMS, 2019-2025
25 companies · $1,781 in 2025
The $1,781 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33.91 · 2021: $36.33 · 2022: $216 · 2023: $937 · 2024: $406 · 2025: $1,781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,781 · Travel and Lodging: $1,343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,780.82 |
| Travel and Lodging | $1,342.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,968.18 | 2022-2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $276.23 | 2023-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $147.48 | 2024-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Actelion Pharmaceuticals US, INC. | $119.96 | 2022-2025 | Opsumit, Uptravi, Opsynvi |
| Genzyme Corporation | $98.60 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $84.97 | 2024-2025 | Dupixent |
| Insmed, INC. | $83.25 | 2021-2025 | Arikayce |
| Harmony Biosciences LLC | $73.32 | 2023 | Wakix |
| Merck Sharp & Dohme LLC | $67.54 | 2024-2025 | Winrevair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.06 | 2023 | Ofev |
| United Therapeutics Corporation | $59.56 | 2024 | |
| Grifols USA, LLC | $59.17 | 2023-2025 | Xembify, Prolastin-C Liquid |
| Mylan Specialty L.P. | $48.89 | 2023-2024 | Yupelri |
| Abbott Laboratories | $45.36 | 2022 | |
| Janssen Pharmaceuticals, INC | $33.91 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $24.86 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Axsome Therapeutics, INC. | $24.75 | 2025 | Sunosi |
| Haemonetics Corporation | $22.44 | 2024 | Teg6s Hemostasis System |
| Bayer Healthcare Pharmaceuticals INC. | $21.05 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.98 | 2025 | Glassia |
| Shionogi INC | $19.73 | 2023 | Fetroja |
| Amgen INC. | $16.66 | 2025 | Tezspire |
| Lilly USA, LLC | $15.08 | 2025 | Zepbound |
| Abbvie INC. | $14.37 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Narayana Gowda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.